

DEAR READER,

This third edition of the BJMO in 2025 once again covers a wide range of topics across the field of oncology.

In the **review** section, *Dr. Gennigens et al.* provide the first part of an overview of the accuracy of **emerging therapies in gynaecological cancers with respect to locally advanced and metastatic cervical cancer**. The authors highlight the promising potential of new innovative treatments for improving survival outcomes for these patients. A second **review** provided by *Dr. Loizidis and Prof. Ignatiadis* outlines the **clinical application of circulating tumour DNA in breast cancer management**. The authors discuss the current indications for circulating tumour DNA as well as ongoing studies in breast cancer.

In the **healthcare** section, *Dr. Pape* highlights the need for more information and support regarding **bowel problems after surgical resection for patients who have survived rectal cancer**. In a second article in this section, *Prof. Meunier* advocates for the “**Right to be forgotten**” for cancer survivors with regard to health-related financial discrimination. This article **exemplifies the system used in Belgium** as one of the most advanced frameworks to prevent this discrimination.

Lastly in this issue, a **congress highlights** article from *Dr. Lybaert* provides an in depth discussion of the highlights of the **Gastrointestinal Cancers Symposium** along with the **clinical relevance of the results of these studies**. *Dr. Punie et al.* provide a second article on the **highlights of new data on systemic therapy for breast cancer** from the **SABCS congress**. This article summarises the most important data regarding systemic breast cancer treatment.

We wish you a pleasant read!

The Publisher